Endocyte, Inc. (NASDAQ:ECYT) VP Christopher P. Leamon sold 23,231 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $5.04, for a total transaction of $117,084.24. Following the completion of the sale, the vice president now directly owns 150,579 shares of the company’s stock, valued at $758,918.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Endocyte, Inc. (ECYT) traded down $0.25 during trading on Thursday, hitting $4.66. 846,700 shares of the stock were exchanged, compared to its average volume of 1,175,467. Endocyte, Inc. has a twelve month low of $1.17 and a twelve month high of $6.55.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Endocyte had a negative return on equity of 38.91% and a negative net margin of 82,235.72%. The firm had revenue of $0.03 million for the quarter. During the same quarter last year, the business posted ($0.21) EPS. The firm’s revenue for the quarter was up .0% on a year-over-year basis. research analysts predict that Endocyte, Inc. will post -1.24 EPS for the current year.

Institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its position in Endocyte by 34.1% during the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 25,003 shares during the period. Spark Investment Management LLC acquired a new position in Endocyte during the second quarter worth about $177,000. LMR Partners LLP acquired a new position in Endocyte during the second quarter worth about $196,000. Bank of New York Mellon Corp grew its position in Endocyte by 4.7% during the first quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after buying an additional 6,469 shares during the period. Finally, Renaissance Technologies LLC grew its position in Endocyte by 284.4% during the first quarter. Renaissance Technologies LLC now owns 192,561 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 142,461 shares during the period. Institutional investors and hedge funds own 17.68% of the company’s stock.

A number of equities research analysts have recently commented on ECYT shares. Zacks Investment Research cut shares of Endocyte from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine raised shares of Endocyte from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Wedbush upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $2.00 to $7.00 in a research note on Tuesday, October 3rd. Finally, Cowen reiterated a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.watchlistnews.com/endocyte-inc-ecyt-vp-sells-117084-24-in-stock/1749911.html.

Endocyte Company Profile

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.